Is Statin Therapy Safe and Effective in Patients with Chronic Kidney Disease?

Author(s): Venkatesh K. Raman, Eleni Geladari, Vasilios Papademetriou*

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 46 , 2017

Become EABM
Become Reviewer
Call for Editor


Chronic kidney disease (CKD) is associated with dyslipidemia and increased cardiovascular risk. This elevated risk for cardiovascular events exists even in the largest subpopulation with milder stages of CKD, prior to the development of significant reductions in renal excretory function. Statin therapy is a critical component of primary and secondary cardiovascular prevention efforts for at-risk patients. Efficacy in the CKD population, however, has appeared less robust across the spectrum of CKD, particularly in hemodialysis patients. This article will review the current state of knowledge on statin therapy in CKD, effects on renal outcomes, safety in this population and alternative lipid therapies.

Keywords: Chronic kidney disease, end-stage renal disease, hemodialysis, statin, cholesterol, lipids.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 01 February, 2018
Page: [7135 - 7140]
Pages: 6
DOI: 10.2174/1381612824666180110100103
Price: $65

Article Metrics

PDF: 29